Aethlon Medical Inc.

Aethlon Medical Inc.

Aethlon Medical Inc. is a publicly listed company on the OTC Markets under the ticker AEMD. It operates in the medical device sector, specializing in the development of the Hemopurifier, a therapeutic tool designed to remove viruses and toxins from blood. The firm is classified as an asset manager in the Altss taxonomy based on its corporate structure, but its primary activity is product development rather than investment management. Aethlon Medical's strategy centers on advancing its Hemopurifier through regulatory approvals and clinical trials. The device targets oncology applications by filtering exosomes that promote tumor growth, and infectious disease applications by capturing viruses such as HIV and hepatitis. The firm has pursued partnerships and grants, including funding from the National Institutes of Health (per the firm's SEC filings). Geographic operations are US-based, with clinical activities in India and other regions. The firm maintains a small team and reports financials through public filings. As a publicly traded entity, its capital structure includes equity financings and public offerings rather than family office-style deployment. Aethlon Medical does not disclose AUM or deployment figures in the context of asset management. Aethlon Medical's structural differentiator is its therapeutic hemofiltration platform, which is distinct from typical family office or asset manager mandates. The firm's model is corporate R&D combined with public equity, driven by scientific milestones rather than investment returns. Succession and governance are determined by public company board structures and SEC regulation.